You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 11, 2025

Drug Price Trends for NDC 66302-0110


✉ Email this page to a colleague

« Back to Dashboard


Best Wholesale Price for NDC 66302-0110

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug NameVendorNDCCountPrice ($)Price/Unit ($)DatesPrice Type
REMODULIN 10MG/ML INJ 20ML VIAL United Therapeutics Corporation 66302-0110-01 20ML 12413.27 620.66350 2020-04-01 - 2025-03-31 FSS
REMODULIN 10MG/ML INJ 20ML VIAL United Therapeutics Corporation 66302-0110-01 20ML 12413.27 620.66350 2021-01-01 - 2025-03-31 FSS
REMODULIN 10MG/ML INJ 20ML VIAL United Therapeutics Corporation 66302-0110-01 20ML 12413.27 620.66350 2022-01-01 - 2025-03-31 FSS
REMODULIN 10MG/ML INJ 20ML VIAL United Therapeutics Corporation 66302-0110-01 20ML 9467.83 473.39150 2022-01-01 - 2025-03-31 Big4
REMODULIN 10MG/ML INJ 20ML VIAL United Therapeutics Corporation 66302-0110-01 20ML 9062.31 453.11550 2021-01-01 - 2025-03-31 Big4
REMODULIN 10MG/ML INJ 20ML VIAL United Therapeutics Corporation 66302-0110-01 20ML 8139.74 406.98700 2020-04-01 - 2025-03-31 Big4
>Drug Name>Vendor>NDC>Count>Price ($)>Price/Unit ($)>Dates>Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies
Showing 1 to 6 of 6 entries

66302-0110 Market Analysis and Financial Projection

Market Analysis and Price Projections for Treprostinil (NDC: 66302-0101)

Overview of Treprostinil

Treprostinil, identified by the National Drug Code (NDC) 66302-0101, is a synthetic prostacyclin primarily used for the treatment of pulmonary arterial hypertension (PAH). It functions as a vasodilator, helping to lower blood pressure in the pulmonary arteries and improve symptoms associated with PAH. Treprostinil can be administered through various routes, including intravenous infusion (Remodulin), inhalation (Tyvaso), and oral tablets (Orenitram)[1][4].

Market Size and Growth

The global treprostinil market has been experiencing significant growth driven by several key factors:

High Demand in North America

North America remains the largest market for treprostinil, largely due to the presence of major manufacturers like United Therapeutics Corporation. In 2017, Remodulin (treprostinil injection) generated $670.9 million in revenue, a 11.4% increase from 2016[1][4].

Strategic Collaborations

Key players are engaging in strategic collaborations, mergers, and acquisitions to enhance market share. For example, United Therapeutics collaborated with MannKind Corporation for the development and commercialization of a dry powder formulation of treprostinil, expected to generate over $95 million[1][4].

New Product Approvals

Recent approvals of new treprostinil products, such as the extended-release tablets Orenitram and the drug-device combination product Trevyent, are expected to further propel market growth[1][4].

Regional Insights

North America

North America continues to dominate the market due to high demand and the presence of major manufacturers. Ongoing research and development activities and the launch of new products in this region are expected to maintain its dominance[1][4].

Other Regions

While North America leads, other regions are also seeing growth, albeit at a slower pace. The global reach of companies like United Therapeutics and Novartis ensures that treprostinil products are available in various markets worldwide[1].

Distribution Channels

The global treprostinil drugs market is segmented based on distribution channels, including:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Mail-Order Pharmacies
  • Online Pharmacies

Each channel plays a significant role in the distribution and accessibility of treprostinil products, with hospital pharmacies and retail pharmacies being the most prominent[1].

Price Projections

Given the current market dynamics, here are some key points to consider for price projections:

Generic Competition

The entry of generic versions, such as Sandoz's generic treprostinil injection, is likely to reduce prices as these generics gain market share. Sandoz has already launched a fully substitutable generic version of Remodulin and has gained market exclusivity for 180 days[1][4].

Medicare Negotiations

The impact of Medicare's negotiated prices, although not directly on treprostinil, could set a precedent for broader price negotiations, potentially affecting the pricing strategy for treprostinil. The Biden-Harris Administration's initiatives to lower drug prices through Medicare negotiations could influence the market[5].

Innovative Formulations

New and innovative formulations, such as the dry powder formulation by MannKind Corporation, may command premium prices initially but could face downward pressure as more competitors enter the market[1][4].

Global Price Comparisons

The significant price difference between the U.S. and other countries may lead to international pricing strategies that could influence U.S. prices over time. Global price comparisons often highlight disparities that can drive policy changes and market adjustments[1].

Predicted Price Trends

Short-Term (2025-2027)

Prices may stabilize or see a slight decrease due to the introduction of generic versions and ongoing negotiations. The average drug price increase has been significant in recent years, but generic competition and regulatory pressures could mitigate this trend[2].

Medium-Term (2028-2030)

As more innovative formulations enter the market, prices could fluctuate based on the adoption rate and competition. New products like Trevyent and the dry powder formulation will influence market dynamics[1][4].

Long-Term (2031 and Beyond)

With the patent cliff looming for several high-revenue drugs, including potentially those in the PAH segment, prices are likely to decrease as more generics and biosimilars become available. The long-term outlook suggests a more competitive market with lower prices[1].

Key Factors Influencing Price

  • Regulatory Changes: Initiatives like the Inflation Reduction Act and Medicare price negotiations can significantly impact drug pricing strategies[5].
  • Market Competition: The entry of generic and biosimilar products will increase competition, leading to potential price reductions[1][4].
  • Innovation: Continuous research and development of new formulations and delivery methods can command premium prices but also face competition and regulatory scrutiny[1][4].

Market Competitors

Key players in the treprostinil market include:

  • United Therapeutics: The primary manufacturer of Remodulin and other treprostinil products.
  • Novartis: Through its division Sandoz, which has launched a generic version of Remodulin.
  • Teva Pharmaceutical Industries Ltd.: Also involved in the development and marketing of treprostinil products[1][4].

Global Market Dynamics

The global treprostinil market is characterized by:

  • High Revenue Generation: In 2018, global sales for treprostinil were valued at around $599 million[4].
  • Strategic Partnerships: Collaborations between companies like United Therapeutics and MannKind Corporation drive innovation and market growth[1][4].

Consumer Impact

High prescription drug prices, including those for treprostinil, create affordability challenges for patients, healthcare payers, employers, and taxpayers. Initiatives to lower drug prices, such as Medicare negotiations and the introduction of generics, aim to address these challenges[2][5].

Illustrative Statistics

  • Revenue Growth: Remodulin generated $670.9 million in revenue in 2017, a 11.4% increase from 2016[1][4].
  • Price Increases: The average drug price increase from January 2022 to January 2023 was 15.2%, translating to $590 per drug product[2].
  • Generic Market Share: Sandoz's generic treprostinil injection has gained market exclusivity for 180 days, which is expected to impact the market share of branded products[1][4].

Expert Insights

"The introduction of generic versions and innovative formulations will significantly impact the pricing dynamics of treprostinil. As the market becomes more competitive, we can expect prices to stabilize or decrease, making the drug more accessible to patients." - Industry Expert[1].

Key Takeaways

  • Market Growth: The treprostinil market is expected to grow driven by new product launches and strategic collaborations.
  • Pricing Dynamics: Prices are likely to be influenced by generic competition, Medicare negotiations, and global price comparisons.
  • Regional Dominance: North America will continue to be the largest market for treprostinil.
  • Innovation: Continuous research and development will lead to new and innovative formulations.

FAQs

1. What is treprostinil used for? Treprostinil is used primarily for the treatment of pulmonary arterial hypertension (PAH), functioning as a vasodilator to lower blood pressure in the pulmonary arteries[1][4].

2. Which region dominates the treprostinil market? North America dominates the treprostinil market due to high demand and the presence of major manufacturers like United Therapeutics Corporation[1][4].

3. How do generic versions impact the market? The entry of generic versions, such as Sandoz's generic treprostinil injection, is likely to reduce prices as these generics gain market share[1][4].

4. What are the predicted price trends for treprostinil? In the short term, prices may stabilize or decrease due to generic competition and negotiations. In the medium term, prices could fluctuate with new formulations. In the long term, prices are likely to decrease with more generics and biosimilars available[1].

5. What initiatives are being taken to lower drug prices? Initiatives such as Medicare price negotiations and the introduction of generics, as part of the Inflation Reduction Act, aim to lower drug prices and make them more affordable for patients[5].

Sources

  1. DrugPatentWatch - Market Analysis and Price Projections for Treprostinil (NDC: 66302-0101)[1].
  2. ASPE - Changes in the List Prices of Prescription Drugs, 2017-2023[2].
  3. United Therapeutics - Quarterly Report 2017[3].
  4. Coherent Market Insights - Treprostinil Drugs Market - Share, Size and Industry Analysis[4].
  5. The White House - Fact Sheet: Biden-Harris Administration Announces New, Lower Prices for First Ten Drugs Selected for Medicare Price Negotiation[5].

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.